PT1994410E - Métodos e estojos para detecção precoce de cancro ou de predisposição a este - Google Patents

Métodos e estojos para detecção precoce de cancro ou de predisposição a este Download PDF

Info

Publication number
PT1994410E
PT1994410E PT07706065T PT07706065T PT1994410E PT 1994410 E PT1994410 E PT 1994410E PT 07706065 T PT07706065 T PT 07706065T PT 07706065 T PT07706065 T PT 07706065T PT 1994410 E PT1994410 E PT 1994410E
Authority
PT
Portugal
Prior art keywords
ser
leu
glu
lys
cancer
Prior art date
Application number
PT07706065T
Other languages
English (en)
Portuguese (pt)
Inventor
Nadir Arber
Original Assignee
Medical Res Fund Of Tel Aviv Sourasky Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Fund Of Tel Aviv Sourasky Medical Ct filed Critical Medical Res Fund Of Tel Aviv Sourasky Medical Ct
Publication of PT1994410E publication Critical patent/PT1994410E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT07706065T 2006-01-31 2007-01-31 Métodos e estojos para detecção precoce de cancro ou de predisposição a este PT1994410E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76337806P 2006-01-31 2006-01-31

Publications (1)

Publication Number Publication Date
PT1994410E true PT1994410E (pt) 2011-01-10

Family

ID=38001788

Family Applications (1)

Application Number Title Priority Date Filing Date
PT07706065T PT1994410E (pt) 2006-01-31 2007-01-31 Métodos e estojos para detecção precoce de cancro ou de predisposição a este

Country Status (12)

Country Link
US (1) US9394569B2 (enExample)
EP (1) EP1994410B1 (enExample)
JP (1) JP5091163B2 (enExample)
AT (1) ATE486285T1 (enExample)
DE (1) DE602007010108D1 (enExample)
DK (1) DK1994410T3 (enExample)
ES (1) ES2355388T3 (enExample)
IL (1) IL193097A (enExample)
PL (1) PL1994410T3 (enExample)
PT (1) PT1994410E (enExample)
SI (1) SI1994410T1 (enExample)
WO (1) WO2007088537A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2355388T3 (es) 2006-01-31 2011-03-25 Medical Research Fund Of Tel Aviv Sourasky Medical Center Métodos para la detección precoz de cáncer.
EP2220505B1 (en) * 2007-12-10 2015-10-28 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of diagnosing cancer
US7888035B2 (en) * 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
EP3181705A1 (en) * 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes
US20140148348A1 (en) 2010-01-13 2014-05-29 Christine Kuslich Dectection of gastrointestinal disorders
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
CA2799757C (en) 2010-05-21 2018-12-04 The Governors Of The University Of Alberta Methods for the assessment of colorectal cancer and colorectal polyps by measurement of metabolites in urine
CN105849276B (zh) 2013-10-01 2020-07-24 生命技术公司 用于检测结构变异体的系统和方法
ES2939298T3 (es) 2017-05-21 2023-04-20 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Combinación de marcadores para el diagnóstico del cáncer
EP3447154A1 (en) * 2017-08-23 2019-02-27 Instytut Genetyki Sadowej Jolanta Powierska - Czarny Method for detection of mutations, polymorphisms and specific dna sequences on dna matrices with dna imaging techniques for the use in medical diagnostics and forensic genetics
WO2019167047A1 (en) * 2018-02-28 2019-09-06 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of diagnosing and treating bladder cancer
IL311084A (en) 2018-11-30 2024-04-01 Caris Mpi Inc New generation molecular characterization
CN110777213A (zh) * 2019-11-05 2020-02-11 武汉科技大学 一种潜伏期胃癌诊断试剂盒
WO2021112918A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor
US11840720B2 (en) 2019-12-23 2023-12-12 Metabolomic Technologies Inc. Urinary metabolomic biomarkers for detecting colorectal cancer and polyps

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07500411A (ja) * 1991-02-05 1995-01-12 ファロク セィディ 癌胎児性抗原を検出するための簡易検査法
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US7081516B2 (en) * 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
AU2003220387A1 (en) * 2002-03-19 2003-10-08 Tularik Inc. Gene amplification in cancer
US20040097448A1 (en) * 2002-11-19 2004-05-20 Isis Pharmaceuticals Inc. Modulation of CD24 expression
WO2005024603A2 (en) * 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
AU2004294547A1 (en) * 2003-11-26 2005-06-16 The Ohio State University Research Foundation Polymorphic CD24 genotypes that are predictive of multiple sclerosis risk and progression
CA2453198A1 (en) 2004-01-07 2005-07-07 Wei-Ping Min Quantification and generation of immune suppressive exosomes
US7666583B2 (en) * 2004-02-19 2010-02-23 Yale University Identification of cancer protein biomarkers using proteomic techniques
ES2355388T3 (es) 2006-01-31 2011-03-25 Medical Research Fund Of Tel Aviv Sourasky Medical Center Métodos para la detección precoz de cáncer.

Also Published As

Publication number Publication date
ATE486285T1 (de) 2010-11-15
US9394569B2 (en) 2016-07-19
IL193097A (en) 2013-03-24
WO2007088537A3 (en) 2007-10-25
ES2355388T3 (es) 2011-03-25
SI1994410T1 (sl) 2011-03-31
DE602007010108D1 (enExample) 2010-12-09
EP1994410B1 (en) 2010-10-27
PL1994410T3 (pl) 2011-12-30
JP5091163B2 (ja) 2012-12-05
IL193097A0 (en) 2009-02-11
WO2007088537A2 (en) 2007-08-09
DK1994410T3 (da) 2011-01-31
JP2009525041A (ja) 2009-07-09
EP1994410A2 (en) 2008-11-26
US20100062450A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
PT1994410E (pt) Métodos e estojos para detecção precoce de cancro ou de predisposição a este
JP6430560B2 (ja) 前立腺癌マーカーとしてのホスホジエステラーゼ4d7
DK2456889T3 (en) Markers of endometrial cancer
CA2712505C (en) Biomarkers for the diagnosis and treatment of pancreatic cancer
US20090317816A1 (en) Methods for identifying risk of breast cancer and treatments thereof
KR20150122731A (ko) 암 전이의 예후 및 치료 방법
JP2010246558A (ja) 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法
JP2011092195A (ja) 卵巣癌の同定、評価、予防および治療のための核酸分子およびタンパク質
US11022612B2 (en) BARD1 isoforms in lung and colorectal cancer and use thereof
US20210395834A1 (en) Abca1 downregulation in prostate cancer
US8216783B2 (en) Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors
KR20150085459A (ko) 대장암 마커로서의 신규 ntrk1 융합유전자 및 이의 용도
JP2009535033A (ja) Cripto−3の検出のための組成物および方法
KR102055350B1 (ko) 대장암의 항암제 내성 진단용 바이오마커 및 이의 용도
EP2112229A2 (en) Methods for identifying risk of breast cancer and treatments thereof